Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217).

Loading...
Thumbnail Image
Issue Date
2014-08
Authors
Gritz, Ellen R
Arnold, Kathryn B
Moinpour, Carol M
Burton-Chase, Allison M
Tangen, Catherine M
Probstfield, Jeffrey F
See, William A
Lieber, Michael M
Caggiano, Vincent
Moody-Thomas, Sarah
Degree
Advisor
Committee Members
Journal Title
Journal ISSN
Volume Title
Abstract
Background: The Prostate Cancer Prevention Trial (PCPT) was a 7-year randomized, double-blind, placebo-controlled trial of the efficacy of finasteride for the prevention of prostate cancer with a primary outcome of histologically determined prevalence of prostate cancer at the end of 7 years. Methods: A systematic modeling process using logistic regression identified factors available at year 6 that are associated with end-of-study (EOS) biopsy adherence at year 7, stratified by whether participants were ever prompted for a prostate biopsy by year 6. Final models were evaluated for discrimination. At year 6, 13,590 men were available for analysis. Results: Participants were more likely to have the EOS biopsy if they were adherent to study visit schedules and procedures and/or were in good health (P < 0.01). Participants at larger sites and/or sites that received retention and adherence grants were also more likely to have the EOS biopsy (P < 0.05). Conclusions: Our results show good adherence to study requirements 1 year before the EOS biopsy was associated with greater odds that a participant would comply with the invasive EOS requirement. Impact: Monitoring adherence behaviors may identify participants at risk of nonadherence to more demanding study end points. Such information could help frame adherence intervention strategies in future trials.
Citation
Gritz ER, Arnold KB, Moinpour CM, Burton-Chase AM, Tangen CM, Probstfield JF, See WA, Lieber MM, Caggiano V, Moody-Thomas S, Szczepanek C, Ryan A, Carlin S, Hill S, Goodman PJ, Padberg RM, Minasian LM, Meyskens FL, Thompson IM Jr. Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer Epidemiol Biomarkers Prev. 2014 Aug;23(8):1638-48. doi: 10.1158/1055-9965.EPI-14-0202. Epub 2014 Jul 15. PMID: 25028457; PMCID: PMC4119542.
Description
Grants
P30CA16672/CA/NCI NIH HHS/United States , P30 CA016672/CA/NCI NIH HHS/United States , U10 CA037429/CA/NCI NIH HHS/United States , UG1 CA189974/CA/NCI NIH HHS/United States , CA37429/CA/NCI NIH HHS/United States